Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.45 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857131 | 0.88 | MAPT (0.42) | MTORPIK3CAPIK3R1RAF1BRAF | |
| SCHEMBL857140 | 0.86 | PIK3CA (0.44) | MTORPIK3CAPIK3R1PIK3CDPIK3CG | |
| SCHEMBL1310540 | 0.76 | PIK3R1 (0.54) | MTORPIK3CAPIK3R1PIK3CBRAF1 | |
| SCHEMBL856713 | 0.76 | CNR2 (0.45) | MTORPIK3CAPIK3CDPIK3CGCYP1A2 | |
| SCHEMBL1309680 | 0.75 | PIK3CA (0.60) | MTORPIK3CAPIK3R1PIK3CBPIK3CD | |
| SCHEMBL1311429 | 0.75 | PIK3CA (0.67) | MTORPIK3CAPIK3R1PIK3CBPIK3CD | |
| SCHEMBL1310725 | 0.73 | PIK3R1 (0.55) | MTORPIK3CAPIK3R1PIK3CBPIK3CD | |
| SCHEMBL855340 | 0.72 | MTOR (0.76) | MTORPIK3CAPIK3R1PIK3CBPIK3CD | |
| SCHEMBL1309849 | 0.70 | PIK3CA (0.67) | MTORPIK3CAPIK3R1PIK3CBPIK3CD | |
| SCHEMBL15886940 | 0.69 | PIK3R1 (0.66) | MTORPIK3CAPIK3R1PIK3CBPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173647-B2 | PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| EP-2118087-B1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| EP-2118087-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008098058-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048547-A1 | PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE | PI4KA, PI4KB, PI4K2A | MTOR 64/4885PIK3CA 5/4885PIK3R1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.